

# **Bacillus Calmette-Guérin (BCG) (OncoTICE®)**

# Preparation of a Full Dose of OncoTICE® and Dividing a Full Dose Into Three Equal Doses Using the ChemoLock™ Closed System Drug Transfer Device

# **Table of Contents**

Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guerin (BCG) (OncoTICE®) Using a ME Medication Administration Kit and ChemoLock™	
Preparation of a Full Dose (50 mg / 1 vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using Chem	
Dividing a Full Dose (50 mg) of Reconstituted Bacillus Calmette-Guérin (BCG) (OncoTICE®) into Three (1/3) Doses Using ChemoLock™	Equal
Dilution of 1/3 Doses (16.7 mg) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) with Normal Saline 0.9 ChemoLock™	_
Administration of 16.7 mg (1/3 Dose) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL Medication Administration Kit and ChemoLock™	
Administration of 16.7 mg (1/3 Dose) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a ChemoL BCG Kit	
Appendix 1: Supplies & Devices	9
References	10

The typical dose used for intravesical instillation is dictated by brand (*refer to protocol by which patient is being treated*):

**OncoTICE**® (*Tice* strain) 1 vial = 50 mg = 1 to 8 x 10<sup>8</sup> CFU;

• full dose = 50 mg (1 x 50 mg vial)

The instructions described in these checklists are by no means intended to be regarded as the only acceptable method of preparing or dividing a dose of OncoTICE®.

Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL BCG Medication Administration Kit and ChemoLock™

# Note:

- As long as the syringe and OncoTICE® vial are NOT disconnected from the MEDXL BCG Medication Administration Kit, it is not necessary to use a Closed System Drug Transfer Device to reconstitute one vial of OncoTICE® and dilute in 45 mL of normal saline [refer to Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL BCG Medication Administration Kit in the Bacillus Calmette-Guérin (BCG) (OncoTICE®) Preparation Instructions during BCG Shortage NOT using a Closed System Drug Transfer Device]
- If dividing the full dose of OncoTICE® into three equal (1/3) doses, then use of a Closed System Drug Transfer Device is recommended

# Supplies:

- √ 1 x OncoTICE® 50 mg vial
- ✓ 1 x Intravenous (IV) solution bag of preservative-free normal saline (NS) 0.9%
- √ 1 x 50 mL BD syringe
  - Note that a 60 mL syringe may be used in place of the 50 mL BD syringe; the total volume in the syringe after dilution of the drug remains at 45 mL
- √ 1 x MEDXL BCG Medication Administration Kit (BCG Kit)
- √ 1 x ChemoLock™ Bag Spike (CL-10)
- √ 1 x ChemoLock™ Spinning Injector (CL-2000S)
- √ 1 x ChemoLock™ Port (CL-2100)

- ★ do NOT remove any ChemoLock™ device from any supply used during reconstitution of BCG as this will open the system, increasing the chance of exposure to BCG
- insert a ChemoLock™ Bag Spike firmly into the administration port of the intravenous solution bag of NS (up to the shoulder of the ChemoLock™ Bag Spike)
- luer the ChemoLock™ Injector onto a 50 mL (BD) syringe (rotate the Injector onto the syringe tip until an audible click is heard and it spins freely)
- attach the ChemoLock™ Injector / syringe assembly to the ChemoLock™ Bag Spike in the NS bag by pushing the two pieces straight together until an audible click is heard
- 4. withdraw 45 mL of NS into the syringe; remove air from the syringe while the ChemoLock™ Injector/syringe is still attached to the ChemoLock™ Bag Spike
- 5. disconnect the ChemoLock™ Injector from the ChemoLock™ Bag Spike by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 6. attach a ChemoLock™ Port to the luer lock end of the BCG Kit; align the 'OFF' arrow with the catheter tip
- 7. attach the OncoTICE® vial to the other end of the BCG Kit
- 8. attach the ChemoLock™ Injector on the NS syringe to the ChemoLock™ Port on the BCG Kit by pushing the two pieces together until an audible click is heard



- 9. with the vial in an upright position, withdraw approximately 1 mL of air from the vial into the syringe and allow approximately 1 mL of NS to flow back into the vial as pressure in the vial equalizes
- 10. allow the OncoTICE® suspension to stand for a few minutes, then gently swirl to suspend
- 11. withdraw the OncoTICE® suspension into the syringe; repeat step 9 as necessary until all drug from the vial has been withdrawn into the syringe
- 12. align the "OFF" arrow with the syringe until ready to administer to the patient
- 13. do not detach the ChemoLock™ Port or the vial from the BCG Kit; do not remove the syringe from the BCG kit if administering the total dose to the patient
- 14. when dividing the dose of OncoTICE®, remove the ChemoLock™ Injector/syringe attachment from the ChemoLock™ Port on the BCG Kit by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 15. the OncoTICE®-filled syringe MUST be labelled with the **beyond use (expiry) date and time**; the prepared dose **MUST** be administered to the patient before the beyond use date and time have passed
- 16. the contents of the syringe MUST be immediately divided into patient-specific doses if applicable (see **Dividing a Full Dose (50 mg) of Reconstituted Bacillus Calmette-Guérin (BCG) (OncoTICE®) into Three Equal (1/3) Doses Using ChemoLock™)** and administered to patients already in the facility ready for their treatment. Leftover BCG must **NOT** be saved for future patients
- 17. dispose of all supplies used to reconstitute BCG as biohazardous waste according to site-specific policies and procedures

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- USE ASEPTIC TECHNIQUE THROUGHOUT

# Preparation of a Full Dose (50 mg / 1 vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using ChemoLock™

# Note:

- As long as the syringe and OncoTICE® vial are NOT disconnected from the MEDXL BCG Medication Administration Kit, it is not necessary to use a Closed System Drug Transfer Device to reconstitute one vial of OncoTICE® and dilute in 45 mL of normal saline [refer to Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL BCG Medication Administration Kit in the Bacillus Calmette-Guérin (BCG) (OncoTICE®) Preparation Instructions during BCG Shortage NOT using a Closed System Drug Transfer Device]
- If dividing the full dose of OncoTICE® into three equal (1/3) doses, then use of a Closed System Drug Transfer Device is recommended

# Supplies:

- √ 1 x OncoTICE® 50 mg vial
- √ 1 x Intravenous (IV) solution bag of preservative-free normal saline (NS) 0.9%
- √ 1 x 50 mL BD syringe
  - Note that a 60 mL syringe may be used in place of the 50 mL BD syringe; the total volume in the syringe after dilution of the drug remains at 45 mL
- √ 1 x ChemoLock™ Bag Spike (CL-10)
- √ 1 x ChemoLock™ Spinning Injector (CL-2000S)
- √ 1 x ChemoLock™ Vial Spike (CL-82)

- do NOT remove any ChemoLock™ device from any supply used during reconstitution of BCG as this will open the system, increasing the chance of exposure to BCG
- insert a ChemoLock™ Bag Spike firmly into the administration port of the intravenous solution bag of NS (up to the shoulder of the ChemoLock™ Bag Spike)
- luer the ChemoLock™ Injector onto a 50 mL (BD) syringe (rotate the Injector onto the syringe tip until an audible click is heard and it spins freely)
- 3. attach the ChemoLock™ Injector / syringe assembly to the ChemoLock™ Bag Spike in the NS bag by pushing the two pieces straight together until an audible click is heard
- 4. withdraw 45 mL of NS into the syringe; remove air from the syringe while the ChemoLock™ Injector/syringe is still attached to the ChemoLock™ Bag Spike
- 5. disconnect the ChemoLock™ Injector from the ChemoLock™ Bag Spike by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 6. attach a ChemoLock™ Vial Spike to the OncoTICE® vial



- 7. attach the ChemoLock™ Injector / NS-filled syringe assembly to the ChemoLock™ Vial Spike by pushing the two pieces straight together until an audible click is heard
- 8. with the vial in an upright position, inject approximately 1 mL of NS into the vial
- 9. allow the OncoTICE® suspension to stand for a few minutes, then gently swirl to suspend
- 10. withdraw the OncoTICE® suspension into the syringe; repeat step 8 as necessary until all drug from the vial has been withdrawn into the syringe
- 11. disconnect the ChemoLock™ Injector from the ChemoLock™ Vial Spike by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 12. the OncoTICE®-filled syringe MUST be labelled with the **beyond use (expiry) date and time**; the prepared dose **MUST** be administered to the patient before the beyond use date and time have passed
- 13. the contents of the syringe MUST be immediately divided into patient-specific doses if applicable (see **Dividing a Full Dose (50 mg) of Reconstituted Bacillus Calmette-Guérin (BCG) (OncoTICE®) into Three Equal (1/3) Doses Using ChemoLock™)** and administered to patients already in the facility ready for their treatment. Leftover BCG must **NOT** be saved for future patients
- 14. dispose of all supplies used to reconstitute BCG as biohazardous waste according to site-specific policies and procedures

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- USE ASEPTIC TECHNIQUE THROUGHOUT

Dividing a Full Dose (50 mg) of Reconstituted Bacillus Calmette-Guérin (BCG) (OncoTICE®) into Three Equal (1/3) Doses Using ChemoLock™

# Supplies:

- ✓ 1 x 50 mL BD syringe containing 45 mL (50 mg) of reconstituted OncoTICE® (prepared following Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL BCG Medication Administration Kit and ChemoLock™ OR Preparation of a Full Dose (50 mg / 1 Vial) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using ChemoLock™)
  - ensure the divided doses will be administered to patients before the beyond use (expiry) date and time recorded on the syringe
- ✓ 2 x 50 mL BD syringes
  - Note that a 60 mL syringe may be used in place of the 50 mL BD syringe; the total volume in the syringe after dilution of the drug remains at 45 mL
- ✓ 2 x ChemoLock<sup>™</sup> Spinning Injectors (CL-2000S)
- √ 1 x ChemoLock™ Double Port Syringe Transfer Set (CL-33)

# Note:

- ★ do NOT remove any ChemoLock™ device from any supply used during division of BCG as this will open the system, increasing
  the chance of exposure to BCG
- 1. attach a ChemoLock™ Spinning Injector to both of the empty 50 mL syringes



- 2. record the same **beyond use (expiry) date and time** that is recorded on the 45 mL syringe of OncoTICE® onto both of the syringes and that the **contents of all three syringes contains 16.7 mg (1/3 dose) of OncoTICE®**; the prepared dose **MUST** be administered to the patient before the beyond use date and time have passed
- 3. attach the ChemoLock™ Injector on the OncoTICE®-filled syringe to one end of the ChemoLock™ Double Port Transfer Set by pushing the Injector onto the Port until an audible click is heard
- 4. attach the ChemoLock™ Injector on one of the empty syringes to the other end of the ChemoLock™ Double Port transfer set by pushing the two pieces straight together until an audible click is heard



- 5. transfer 15 mL (16.7 mg) of OncoTICE® suspension into the empty syringe; remove all air from the syringe while the entire system is still attached
- 6. disconnect the syringe containing 15 mL (16.7 mg) of OncoTICE® from the ChemoLock™ Double Port Transfer Set by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 7. repeat steps 4-6 to prepare the next syringe containing 1/3 of the full dose (16.7 mg) of OncoTICE®; the original syringe contains the final 1/3 divided dose of OncoTICE®
- 8. dispose of all supplies used to divide a full dose of OncoTICE® into three equal doses as biohazardous waste according to site-specific policies and procedures

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- > USE ASEPTIC TECHNIQUE THROUGHOUT

# Dilution of 1/3 Doses (16.7 mg) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) with Normal Saline 0.9% Using ChemoLock™

# Supplies:

- ✓ 3 x 50 mL BD syringes containing 1/3 dose (15 mL / 16.7 mg) of reconstituted OncoTICE®
  - Note that a 60 mL syringe may be used in place of the 50 mL BD syringe; the total volume in the syringe after dilution of the drug remains at 45 mL
- ✓ 1 x Intravenous (IV) bag of preservative-free normal saline (NS) 0.9% with a ChemoLock™ Bag Spike inserted into the administration port (can use the same IV bag that was used to reconstitute the OncoTICE®)

# Note:

- do **NOT** remove any ChemoLock™ device from any supply used during dilution of BCG as this will open the system and increase the chance of exposure to BCG
- 1. attach the Injector on one of the 1/3 dose (15 mL / 16.7 mg) syringes to the ChemoLock™ Bag Spike in the NS bag by pushing the two pieces straight together until an audible click is heard
- 2. withdraw NS into the syringe until the total volume in the syringe is 45 mL
- 3. carefully remove air only (NOT drug) from the syringe while the ChemoLock™ Injector/syringe is attached to the ChemoLock™ Bag Spike
- 4. disconnect the ChemoLock™ Injector from the ChemoLock™ Bag Spike by squeezing the release clips on the ChemoLock™ Injector (the ChemoLock™ Injector will automatically disconnect; do NOT pull apart when releasing)
- 5. repeat steps 1-4 until all three syringes contain 1/3 OncoTICE® doses (16.7 mg) diluted to 45 mL with NS
- 6. dispose of all supplies used to dilute BCG as biohazardous waste according to site-specific policies and procedures

# Party Land

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- ▶ USE ASEPTIC TECHNIQUE THROUGHOUT

# Administration of 16.7 mg (1/3 Dose) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a MEDXL BCG Medication Administration Kit and ChemoLock™

# Supplies:

- ✓ 3 x 50 mL syringes containing 45 mL of 16.7 mg (1/3 dose) dilute OncoTICE® suspension (labelled with the **beyond use (expiry)** date and time and the 16.7 mg dose) attached to ChemoLock™ Injectors
- √ 3 x MEDXL BCG Medication Administration Kits (BCG Kit)
- √ 3 x ChemoLock<sup>™</sup> Ports (CL-2100)

# Note:

- ★ do NOT remove any ChemoLock™ device from any supply used during administration of BCG as this will open the system, increasing the chance of exposure to BCG
- 1. check to ensure the OncoTICE® suspension has not expired (not past the **beyond use (expiry) date and time** recorded on the syringe); the prepared dose **MUST** be administered to the patient before the beyond use date and time have passed
- 2. leftover BCG must NOT be saved for a future patient
- 3. attach a ChemoLock™ Port to the luer lock end of each of the BCG Kits; align the 'OFF' arrow with the vial adapter end of the BCG Kit
- 4. immediately before administering the dose to the patient, attach the ChemoLock™ Injector on a syringe containing the dose of OncoTICE® to the ChemoLock™ Port on the BCG Kit by pushing the two pieces straight together until an audible click is heard



- 5. administer the OncoTICE® to the patient as per site protocol
- 6. dispose of all supplies used to administer BCG as biohazardous waste according to site-specific policies and procedures

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- > USE ASEPTIC TECHNIQUE THROUGHOUT

# Administration of 16.7 mg (1/3 Dose) of Bacillus Calmette-Guérin (BCG) (OncoTICE®) Using a ChemoLock™ BCG Kit

# Supplies:

- ✓ 3 x 50 mL syringes containing 45 mL of 16.7 mg (1/3 dose) dilute OncoTICE® suspension (labelled with the **beyond use (expiry)** date and time and the 16.7 mg dose) attached to ChemoLock™ Injectors
- ✓ 3 x ChemoLock™ 7.5" (19 cm) Extension Sets w/ChemoLock™ Port, Clamp, Graduated Adapter (CL-3967) (ChemoLock™ BCG Kit)

# Note:

- ★ do NOT remove any ChemoLock™ device from any supply used during administration of BCG as this will open the system, increasing the chance of exposure to BCG
- 1. check to ensure the OncoTICE® suspension has not expired (not past the **beyond use (expiry) date and time** recorded on the syringe); the prepared dose **MUST** be administered to the patient before the beyond use date and time have passed
- 2. leftover BCG must **NOT** be saved for a future patient
- 3. Squeeze the clamp on the ChemoLock™ BCG Kit closed
- 4. immediately before administering the dose to the patient, attach the ChemoLock™ Injector on a syringe containing the dose of OncoTICE® to the ChemoLock™ Port on the ChemoLock™ BCG Kit by pushing the two pieces straight together until an audible click is heard



- open the clamp on the ChemoLock™ BCG Kit and administer the OncoTICE® to the patient as per site protocol
- 6. dispose of all supplies used to administer BCG as biohazardous waste according to site-specific policies and procedures

- BCG must be administered within 2 hours of the start of reconstituting the drug in the vial<sup>1,2</sup>
- USE ASEPTIC TECHNIQUE THROUGHOUT

# **Appendix 1: Supplies & Devices**

# ICU Medical's ChemoLock™

For more information on ICU Medical's ChemoLock™ supplies visit: <a href="http://www.icumed.com/products/oncology/hazardous-drug-closed-systems-and-cstds/chemolock.aspx">http://www.icumed.com/products/oncology/hazardous-drug-closed-systems-and-cstds/chemolock.aspx</a>

# ChemoLock™ Spinning Injector (CL-2000S)



The ChemoLock™ Injector ensures a **closed drug transfer**. The Injector is attached to a standard luer lock syringe. The Injector is available in a spinning and non-spinning design. The spinning design prevents accidental disconnection of the Injector during hazardous drug preparation and administration. The priming volume of the ChemoLock™ Injector is 0.34 mL. The ChemoLock™ Injector has been tested to and is approved for up to 10 activations.

# ChemoLock™ Bag Spike (CL-10)



The ChemoLock™ Bag Spike is inserted into the administration port of an infusion solution bag. It has a built-in ChemoLock™ Port to facilitate a **leak-proof connection** for transfer of solution into and out of an infusion solution bag. The priming volume of the ChemoLock™ Bag Spike is 0.43 mL. The Port on the ChemoLock™ Bag Spike has been tested to and is approved for up to 10 activations.

# ChemoLock™ Port (CL-2100)



The ChemoLock™ Port attaches to the same luer locking device that syringes luer lock onto, providing a **leak-proof** connection for safe drug transfer via injection or infusion. The priming volume of the ChemoLock™ Port is 0.1 mL. The Port has been tested to and is approved for up to 10 activations.

# ChemoLock™ Double Port Syringe Transfer Set (CL-33)



The ChemoLock™ Double Port Syringe Transfer Set facilitates a safe and efficient transfer of solution from one syringe to another. The Ports on the ChemoLock™ Double Port Syringe Transfer Set have been tested and are approved for up to 10 activations.

# ChemoLock™ 7.5" (19 cm) Extension Set w/ChemoLock™ Port, Clamp, Graduated Adapter (CL-3967) (ChemoLock™ BCG Kit)

The ChemoLock™ Extension Set w/ChemoLock™ Port, Clamp, Graduated Adapter may be used for bladder instillation of Bacillus Calmette-Guérin (BCG). The priming volume of the ChemoLock™ Extension Set is 1.5 mL. The Port on the ChemoLock™ Extension Set has been tested and is approved for up to 10 activations.



# Non- ChemoLock™

Bacillus Calmette-Guérin (BCG) (OncoTICE®)- 1 to 8 x 108 CFU (= 50 mg/vial) (FULL dose)

MEDXL Medication Administration Kit (used to facilitate reconstitution and withdrawal of BCG)



# Intravenous Solution Bag of Preservative-free Normal Saline 0.9%

**50 mL BD Syringes** (Note that 60 mL syringes may be used in place of the 50 mL BD syringes; the total volume in the syringe(s) after dilution of the drug remains at 45 mL)

# References

1.	Merck Canada Inc. OncoTICE® product monograph. Kirkland, Quebec; 29 April 2019	
	merek canada merentez product menegrapin kirkiana, Quebec, 23 April 2013	

2.	The United States Pharmacopeial Convention, Inc. General Chapter 797: Pharmaceutical compounding - sterile preparations
	Draft, USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.: 2019